Teva unveils generic Vesicare tablets
Teva Pharmaceutical announced the launch of its generic version of Vesicare.
The tablets, which are available in 5 mg and 10 mg in the United States, are a solifenacin succinate indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and urinary frequency.
“About 33 million Americans have overactive bladder.2 We’re proud to offer another treatment option for this common condition,” said Brendan O’Grady, EVP and Head of North America Commercial.
Overactive bladder, or OAB, is often characterized as the strong sudden urge to urinate, that often is difficult to control, the company said.
Vesicare tablets had annual sales of more than $955 million in the United States, according to IQVIA data as of February 2019.
The tablets, which are available in 5 mg and 10 mg in the United States, are a solifenacin succinate indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and urinary frequency.
“About 33 million Americans have overactive bladder.2 We’re proud to offer another treatment option for this common condition,” said Brendan O’Grady, EVP and Head of North America Commercial.
Overactive bladder, or OAB, is often characterized as the strong sudden urge to urinate, that often is difficult to control, the company said.
Vesicare tablets had annual sales of more than $955 million in the United States, according to IQVIA data as of February 2019.